[CANCER RESEARCH 53. 3217-3220. July 15. 1993]
Advances in Brief
Expression of Mutated Epidermal Growth Factor Receptor by Non-Small Cell
Lung Carcinomas1
Irma E. Garcia de Palazzo,2 Gregory P. Adams, Padma Sundareshan, Albert J. Wong, Joseph R. Testa,
Darell D. Bigner, and Louis M. Weiner3
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 ¡I.E. G„G. P. A., P. S.. A. J. W., J. R. T., L M. W.¡,and the Preuss Laboratory
for Brain Tumor Research. Duke University Medical Center, Durham, North Carolina 27710 ¡D.D. B.¡
10). Due to its high expression by a number of neoplasms, the EGFR
has been utilized as a tumor-associated target for tumor detection and
Abstract
The development of novel immunotherapy strategies for non-small cell
lung cancer (NSCLC) will be facilitated by the identification of tumorspecific targets. Although the epidermal growth factor receptor (EGFR) is
overexpressed in many cases of NSCLC, its wide distribution in normal
tissue may limit its suitability as an immunotherapeutic target. However,
mutations within the EGFR that are unique to malignancies may provide
specific targets for immunotherapeutic
intervention. For example, one
mutant form, the type III deletion mutant of the EGFR, that has been
identified in glioblastomas contains a novel peptide sequence in its extra
cellular domain which is detectable by anti-peptide antisera. In this study,
the prevalence of this type of mutation of the EGFR in NSCLC was
determined. Thirty-two frozen sections of primary NSCLC were examined
by immunocytochemistry to determine the presence of native and mutated
EGFR. Native EGFR was overexpressed in 12 of the 32 sections and a
diffuse cellular distribution of the EGFR type III deletion mutation was
identified in five (16%) of the specimens (2 of 13 squamous, 2 of 2 mixed,
0 of 10 adenocarcinoma, and 1 of 7 undifferentiated). This mutated EGFR
was not detected in sections of normal breast, lung, skin, ovary, colon,
kidney, endometrium, and placenta. The type III EGFR deletion mutant,
expressed in some cases of NSCLC, may be a molecularly defined, tumorspecific antigen in lung cancer.
Introduction
NSCLC4 is the most frequent cause of cancer death in the United
States. Cure rates are directly related to clinical stage (70% for Stage
I, decreasing to less than 5% for Stage IIIB) (1). Therapy using
various permutations of surgery, radiotherapy, and chemotherapy has
had limited effects on cure rates and median survival in advanced
stages of NSCLC (1). Clearly, novel therapeutic targets and agents are
needed for the management of this disease. One such approach in
volves immunotherapy directed against antigens which are either se
lectively expressed or over expressed in malignant cells. A number of
potential targets have been identified; the potential suitability of the
EGFR as a target has been the subject of intensive study.
Overexpression of EGFR has been associated with a number of
neoplasms, including breast carcinoma (2, 3), adenocarcinoma and
squamous cell carcinoma of the lung (3-7), large cell carcinoma of the
lung (3, 5, 6), gliomas (8), and a variety of bladder (9, 10) and
gynecological tumors (11). In both bladder and breast cancer, a poor
prognosis has been correlated with high expression of EGFR (2, 3, 9,
Received 3/19/93; accepted 6/3/93.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance with
18 U.S.C. Section 1734 solely to indicate this fact.
1 Supported by National Cancer Institute Grants CA06927, CA50633. and CA51880
and the Bernard A. and Rebecca S. Bernard Foundation.
2 Present address: Department of Pathology and Laboratory Medicine, Temple Uni
versity. Philadelphia. PA 19144.
' To whom requests for reprints should be addressed, at Fox Chase Cancer Center.
Department of Medical Oncology. 7701 Burholme Avenue, Philadelphia, PA 19111.
4 The abbreviations used are: NSCLC. non-small cell lung cancer; EGFR, epidermal
growth factor receptor; PBS, phosphate-buffered saline; ISCN, International System for
Human Cytogenetic Nomenclature (1985).
therapy. In imaging studies performed in patients with squamous cell
carcinoma of the lung, over 94% of primary lesions and sites of
presumed métastaseswere detected when doses of 40 mg or more
monoclonal antibody were utilized (12, 13). In mice bearing a lethal
inoculum of tumor cells expressing EGFR, treatment with transform
ing growth factor a-Pseudomonas exotoxin 40 fusion proteins more
than doubled median survival. The fusion protein did not significantly
prolong the survival of mice inoculated with EGFR-negative tumor
cells (14, 15).
Amplification of the EGFR gene has frequently been associated
with EGFR overexpression in gliomas (8, 16, 17) and has been re
ported in squamous cell carcinomas (including those of the lung)
(18-20), breast carcinomas (21), and bladder tumors (9). Rearranged
or truncated forms of EGFR have been identified and are often asso
ciated with gene amplification in gliomas (22-26). To date, three
truncated forms of EGFR have been reported. The type I deletion
mutant lacks the majority of the extracellular domain and is unable to
bind epidermal growth factor (26). The type II deletion mutant con
tains an in-frame deletion of 83 amino acids (520-603) in domain IV
of its extracellular domain and is capable of binding epidermal growth
factor and transforming growth factor a (23). The type III deletion
mutant, reported to occur in 17% of the glioblastomas screened by
Humphrey et al. (22), appears to be the most prevalent. This mutation
generates a fusion junction sequence which is reported to be unique to
malignancies. This sequence results from an in-frame deletion of 267
amino acids (from amino acids 29-296) spanning the first and second
extracellular domains of the receptor (22, 26, 27). A synthetic peptide
spanning the deletion junction (H-Leu-Glu-Glu-Lys-Lys-Gly-AsnTyr-Val-Val-Thr-Asp-His-Oh)
has been used to raise antisera spe
cific for this mutant protein. To determine if this mutated growth
factor receptor merits consideration as a tumor-specific target in
NSCLC, 32 sections of primary NSCLC were studied for the presence
of the type III EGFR deletion mutation.
Materials and Methods
Antibodies. Rabbit and goat antiserum specific for the EGFR type III
deletion sequence were prepared as described (22). Briefly, a 14-amino acid
peptide spanning the predicted amino acid sequence of the fusion junction was
synthesized, purified, and chemically conjugated to keyhole limpet hemocyanin. Animals were immunized with a 1; 1 emulsion of the conjugate in PBS and
complete Freund's adjuvant. Boosts were performed on day 33 with conjugate
in a 1:1 emulsion with incomplete Freund's adjuvant. The animals were bled
and the anti-peptide
antibody was purified from the antisera on a peptide-
Sepharose affinity column.
Immunohistochemistry.
Frozen sections of NSCLC and normal tissues
were obtained from the Fox Chase Cancer Center Tumor Bank. The human
glioblastoma multiforme xenograft (D-270 MG-X), expressing the type III
EGFR deletion mutation, was utilized as a positive control. The sections were
stained with hematoxylin-eosin to evaluate histology. Five-urn sections were
fixed for 20 min in cold acetone and air-dried at room temperature. The
3217
Downloaded from cancerres.aacrjournals.org on August 20, 2015. © 1993 American Association for Cancer
Research.
MUTATED
EGFR
IN NON-SMALL
sections were then incubated in Tissue Conditioner Reagent (Biomeda Immunohistochemical Staining Kit, Foster City, CA) for 10 min at room tempera
ture. A blocking reagent (normal rabbit or goat serum) was then added and the
sections were incubated at room temperature for 30 min. The blocking reagent
was blotted and the samples were rinsed with 0.01 MPBS, pH 7.2. The sections
were then incubated overnight at 4°Cwith 5 fxg/ml of primary antisera reactive
with the type 111deletion junction sequence, normal rabbit/goat serum, or 3
fig/ml of affinity purified rabbit antibody to native EGFR (Ab-4; Oncogene
Science. Ine, Manhasset, NY). After the slides were washed with PBS, 100 fil
of a 1:1 dilution of biotinylated goat anti-rabbit IgG (BioGenex Laboratories,
San Ramon. CA) or rabbit anti-goat IgG (Biomeda) as appropriate were ap
plied and allowed to incubate at room temperature for 45 min. The sections
then were washed twice with PBS and incubated with 100 ju.1of streptavidin
alkaline phosphatase for 45 min at room temperature. They again were washed
with PBS and incubated with 100 /¿Iof Fast Red Chromogen (naphthol
phosphate) (BioGenex Laboratories). The slides were washed in PBS and
coumerstained with Mayer's hematoxylin (Sigma Diagnostics, St. Louis, MO)
for 5 min. The validity of immunohistochemical detection of cells expressing
the type III EGFR deletion mutation in gliomas, using these antisera, previ
ously has been confirmed by Western blot analysis (22).
Karyolypic Analysis. In one case in which a fresh specimen was available,
tissue was disaggregated by mechanical means (28). Actively growing cells
were arrested in metaphase by exposure to 0.03 fig/ml colcemid (GIBCO
Laboratories) for 16-20 h. Cells were then treated with a hypotonie solution of
0.075 M KC1 for 20 min at 37°C. They were fixed in a 3:1 solution of
rnethanol:glacial
acetic acid. Chromosomes
were analyzed using a G-banding
technique (29). Chromosome identification and karyotypic designation
performed in accordance with the ISCN (30).
were
Results
Immunohistochemistry.
Twelve of the 32 sections (38%) of
NSCLC were stained by affinity purified rabbit antibody to native
EGFR (Ab-4) by the immunoperoxidase method (Table 1). Addition
ally, 5 of the 12 (16% overall) specimens with high levels of native
EUFR also diffusely expressed the type III deletion mutant. Expres
sion of this deletion mutant was limited to malignant squamous epi
thelial cells and was not observed in cells with adenocarcinoma dif
ferentiation. In the two positive cases of adenosquamous carcinoma,
both native EGFR and the deletion mutant were observed only in the
squamous cell component (Fig. 1). In the positive specimens, all of the
squamous cells stained positive for the deletion mutant. All cells
which were found to express the deletion mutant also reacted with the
rabbit antiserum to native EGFR. The type III deletion mutant was
found to be predominantly associated with the cellular membrane,
although in some cases cytoplasmic staining was observed. Normal
tissue samples were screened for the presence of both native EGFR
and the deletion mutant. Native EGFR was found to be highly ex
pressed on skin (2) and endometrium (2), diffusely expressed on
scattered cells in the lungs (2) and the colon (3), and not observed on
breast (3), ovary (3), kidney (2), and placenta (5). Antiserum directed
against the type III deletion mutant did not bind to any of the above
normal tissues.
Table I hnmunt>histochernical detection of native EGFR and EGFR type III deletion
mutant expressed in non-small cell lung carcinoma
EGFRHistologySquamous
Expression of
of mutant*15
Adenosquamous
2
2
AdcnocarcmomaUndifferemiatedTotaln"13
10732Native5 2312Mutant2
2C
015%
" Number of samples.
rt Percentage of samples positive for mutant.
' Positive staining only observed on squamous component.
100
01416
CELL
LUNG CARCINOMA
Karyotypic Analysis. One sample of squamous cell carcinoma,
positive for expression of the type III deletion mutant, was available
for karyotypic analysis. This specimen was found to be near triploid.
Most cells examined had four copies of chromosome 7 plus two
copies of a translocation derivative, der(2)t(2;7), containing an extra
portion of most of the short arm of chromosome 7 (Fig. 2). The
derivative included the region containing the EGFR gene, presumably
resulting in six copies of the gene/cell.
Discussion
This study provides a preliminary assessment of the prevalence of
EGFR type III deletion mutant expression in NSCLC. The mutant was
present in 16% of all NSCLC specimens we tested and in 42% of the
cases in which overexpression of the EGFR was detected. The prev
alence of the EGFR type III deletion mutant in NSCLC may actually
be greater than reported here, because immunocytochemistry tech
niques are dependent upon both the sensitivity of the antibodies and
detection systems which are used. For example, in this assay, we
observed native EGFR expression in 38% of the NSCLC samples
examined. However, EGFR expression in NSCLC, as detected by
immunocytochemistry, has been observed in 52-83% of specimens
studied using other reagents (9, 31 ).
Expression of the deletion mutant was observed only in malignant
squamous epithelial cells. In the cases of adenosquamous carcinoma
studied, only the squamous component was positively stained. Normal
breast, lung, skin, ovary, colon, and endometrium failed to react with
antiserum against the deletion mutant fusion junction. The staining
pattern of the positive cells revealed that the predominant expression
of the EGFR type III deletion mutant was membrane associated.
While cytoplasmic staining was observed in some cases, nuclear stain
ing was never observed. Expression of the type III deletion mutant
was confirmed by Western blot analysis in the two cases where frozen
tissue blocks were available (results not shown).
Cytogenetic analysis of one squamous cell carcinoma revealed
polysomy 7 and extra copies of most of 7p; the latter were contained
within two identical translocation derivatives, der(2)t(2;7) (Fig. 2).
The breakpoint on chromosome 7 in the der(2)t(2;7) is at 7pl 1.2-pl2,
which is near the location of the EGFR gene, but we do not know if
this structural rearrangement has disrupted the EGFR locus. In a
previous study, we observed polysomy for all or part of the short arm
of chromosome 7 in 20 of 30 (67%) NSCLC specimens (32). The
shortest region of overlap of partial gains of 7p was at region
7pl 1—>pl3,where the EGFR gene is located (33). While an increase
in the number of copies of EGFR might be expected to manifest itself
in elevated expression of this gene, the correlation between polysomy
of 7p and increased EGFR levels in NSCLC will require further study.
The type III deletion mutant appears to be a promising target for
therapy. Its fusion junction sequence is immunogenic. It is located
near the amino-terminus of the extracellular domain, rendering it
easily accessible to monoclonal antibodies. The detection of the
EGFR type III deletion mutant by immunohistochemistry correlates
extremely well with Western blot analysis and molecular detection of
the deletion in tumor samples (22). Furthermore, antiserum directed
against this sequence on EGFR type III mutant-expressing glioma
cells (D-270 MG-X) has been demonstrated to be completely inter
nalized within 60 min (22), making this type III EGFR mutant po
tentially useful as a target for immunotoxin therapy.
The frequency of expression of the EGFR type III deletion mutant
in NSCLC (16%) is very similar to that reported in glioblastomas
(17%) (22) and suggests that this deletion mutant may occur in a
spectrum of EGFR-overexpressing malignancies. If this prevalence is
verified by the study of more NSCLC samples, as many as 20,000
individuals annually afflicted with NSCLC in the United States will
3218
Downloaded from cancerres.aacrjournals.org on August 20, 2015. © 1993 American Association for Cancer
Research.
MUTATED
EGFR
IN NON-SMALL
CELL LUNG CARCINOMA
•¿
Fig. 1. Adenosquamous carcinoma of the lung.
At squamous component of the tumor. Tissue was
stained as described in "Methods and Materials"
using a biotinylated goat anti-rabbit IgG system
following incubation with primary antibody to the
type III deletion mutant. B, adenocarcinoma com
ponent of the same tumor. Sections were treated as
described above. Note that this component shows
no reactivity for the type III deletion mutant anti
body. Frozen sections; Fast Red with hematoxylin
counterstain ( X 500).
B
express this deletion mutant and may be candidates for treatments
which exploit the presence of this antigen. Mutations of the EGFR
would not be likely to occur in normal tissues and have not been
detected in the limited panel which has been examined thus far. Thus,
mutated growth factor receptors may be molecularly defined tumorspecific antigens. If this is indeed the case, the EGFR type III deletion
mutant may provide a unique and powerful target for a number of
forms of cancer detection and treatment, since the lack of antigenic
targets on normal tissue should reduce the uptake of reagents and
resultant toxicity to nontargeted tissues.
These studies show that immunogenic mutations of the EGFR can
be detected in at least two types of malignancies. Additional malig
nancies may be found to express the type III deletion mutation. Other
mutations in the EGFR extracellular domain may be identified by
systematically analyzing NSCLC and other tumor samples in which
gene amplification of the EGFR is noted. Finally, it is possible that
other growth factor receptors may undergo similar patterns of deletion
mutations in the setting of malignant transformation, providing addi
tional examples of molecularly defined, tumor-specific antigens
which can be exploited as new therapeutic targets.
References
1. Minna, J. D., Pass, H., Glatstein, E., el ai. Cancer of the Lung, In: V. T. De Vita,
S. Hellman, and S. A. Rosenberg (eds.), Cancer, Principles and Practice of Oncology,
pp. 591-705. J.B. Lippincott Company, Philadelphia, 1989.
2. Sainsbury, J. R. C., Famdon, J. R., Sherbet, G. V., and Harris, A. L. Epidermalgrowth-factor receptors and oestrogen receptors in human breast cancer. Lancet, i1:
B
Fig. 2. Chromosomes 2 and 7 from two different metaphase spreads (A and B) from a
squamous cell lung carcinoma. Each metaphase has 3 or 4 copies of normal chromosome
7 and two copies of a translocation derivative chromosome 2 containing most of the short
arm of chromosome 7 translocated to the distal end of chromosome 2 (arrows).
365-366, 1985.
3. Harris, A. L. EOF receptor (EGFR) expression in human primary cancers. Proc. Am.
Assoc. Cancer. Res., 31: 458-460, 1990.
4. Berger, M. S., Gullick, W. J., Greenfield, C., Evans, S., Addis, B. J., and Waterfield,
M. D. Epidermal growth factor receptors in lung tumours. J. Pathol., 752: 297-307,
1987.
5. Véale,
D., Ashcroft, T., Marsh, C., Gibson, G. J., and Harris, A. L. Epidermal growth
factor receptors in non-small cell lung cancer. Br. J. Cancer, 55: 513-516, 1987.
6. Véale,D., Kerr, N., Gibson, G. J., and Harris, A. L. Characterization of epidermal
growth factor receptor in primary human non-small cell lung cancer. Cancer Res., 49:
1313-1317, 1989.
7. Cowley. G., Smith, J. A., Gusterson, B., Hendler, F., and Ozanne, B. The amount of
EGF receptor is elevated in squamous cell carcinomas. In: A. J. Levine, G. F. Vande
Woude, W. C. Topp, and J. D. Watson (eds.). Cancer Cells, 1. The Transformed
Phenotype. pp. 5-10. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1984.
8. Wong, A. J., Bigner, S. H., Bigner, D. D., Kinzler, K. W., Hamilton, S. R., and
Vogelstein, B. Increased expression of the epidermal growth factor receptor gene in
malignant gliomas is invariably associated with gene amplification. Proc. Nati. Acad.
Sci. USA, 84: 6899-6903, 1987.
9. Berger, M. S.. Greenfield. C., Gullick, W. J., Haley, J., Downward, J., Neal, D. E.,
Harris, A. L., and Waterfield, M. D. Evaluation of epidermal growth factor receptors
in bladder tumours. Br. J. Cancer, 56: 533-537. 1987.
10. Neal, D. E.. Marsh, C., Bennett, M. K., Abel, P. D., Hall, R. R., Sainsbury, J. R. C.,
and Harris, A. L. Epidermal-growth-factor receptors in human bladder cancer: com
parison of invasive and superficial tumours. Lancet, i: 366-368, 1985.
11. Gullick, W. J., Marsden, J. J., Whittle. N., Ward, B., Bobrow, L., and Waterfield. M.
3219
Downloaded from cancerres.aacrjournals.org on August 20, 2015. © 1993 American Association for Cancer
Research.
MUTATED
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
EOFR
IN NON-SMALL
D. Expression of human epidermal growth factor receptors on human cervical, ova
rian, and vulval carcinomas. Cancer Res., 46: 285-292, 1986.
Divgi, C. R., Welt, S., Kris, M., Real, F. X., Yeh, S. D. J., Gralla R., Merchant, B..
Schweighart. S., Unger. M., Larson. S. M., and Mendelsohn, J. Phase I and imaging
trial of Indium 111-labeled anti-epidermal growth factor monoclonal antibody 225 in
patients with squamous cell lung carcinoma. J. Nati. Cancer Inst., 83: 97-104. 1991.
Mendelsohn. J. Anti-epidermal growth factor receptor monoclonal antibodies as po
tential anti-cancer agents. J. Steroid Biochem. Mol. Biol. 37: 889-892. 1990.
Heimbrook. D. C.. Stirdivant. S. M., Ahem, J. D.. Balishin, N. L., Patrick. D. R.,
Edwards. G. M.. Defeo-Jones. D.. FitzGerald, D. J., Pastan. I., and Oliff. A. Trans
forming growth factor ct-Pseudomonas exotoxin fusion protein prolongs survival of
nude mice bearing tumor xenografts. Proc. Nati. Acad. Sci. USA, 87: 4697-4701.
1990.
Chaudhary. V. K.. FitzGerald. D. J.. Adhya, S., and Pastan. I. Activity of a recombi
nant fusion protein between transforming growth factor type a and Pseudomtmas
toxin. Proc. Nati. Acad. Sci. USA, 84: 4538^4542, 1987.
Chaffanet, M., Chauvin, C.. Lane. M.. Berger. F.. Chedin. M.. Rost. N.. Nissou. M. F.,
and Bcnabid. A. L. EOF receptor amplification and expression in human brain
tumours. Eur. J. Cancer, 28: 11-17. 1992.
Lieberman. T. A., Nusbaum. H. R.. Razón.N.. Kris. R., Lax. I., Soreq. H.. Whittle. N.,
Waterfield. M. D.. Ullrich. A., and Schlessinger. J. Amplification, enhanced expres
sion and possible rearrangement of EGF receptor gene in primary human brain
tumours of glial origin. Nature (Lond.), 313: 144-147, 1985.
Ozanne, B.. Richards, C. S., Hendler. F.. Bums. D.. and Gusterson. B. Over-expres
sion of the EGF receptor is a hallmark of squamous cell carcinomas. J. Pathol., 149:
9-14, 1986.
Ozanne. B., Schum. A.. Richards, C. S., et al. In: Cancer Cells 111.Growth Factors and
Transformation, pp. 41—49.Cold Spring Harbor. NY: Cold Spring Harbor Laboratory.
1985.
Hunts, J.. Ueda, M., Ozawa, S., Abe, O.. Pastan. I., and Shimizu, N. Hyperproduction
and gene amplification of the epidermal growth factor receptor in squamous cell
carcinomas. Jpn. J. Cancer Res.. 76: 663-666, 1985.
Ro, J.. North, S. M., Gallick. G. E., Hortobagyi. G. N.. Gutterman. J. U., and Blick.
M. Amplified and overexpressed epidermal growth factor receptor gene in uncultured
primary human breast carcinoma. Cancer Res., 48: 161-164, 1988.
Humphrey. P. A.. Wong, A. J., Vogelstein, B., Zalutsky, M. R.. Fuller, G. N.. Archer,
G. E., Friedman. H. S.. Kwatra. M. M.. Bigner. S. H.. and Bigner. D. D. Anti-synthetic
CELL
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
LUNG CARCINOMA
peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth
factor receptors in human glioblastoma. Proc. Nati. Acad. Sci. USA. 87: 4207-4211,
1990.
Humphrey, P. A., Gangarosa, L. M., Wong, A. J., Archer, G. E., Lund-Johansen, M.,
Bjerkvig, R.. Laerum. O-D.. Friedman, H. S., and Bigner, D. D. Deletion-mutant
epidermal growth factor receptor in human gliomas: effect of type II mutation on
receptor function. Biochem. Biophys. Res. Commun., 178: 1413-1420, 1991.
Maiden. L. T.. Novak. U.. Kaye, A. H., and Burgess. A. W. Selective amplification of
the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma
multiforme. Cancer Res., 48: 2711-2714. 1988.
Yamazaki. H., Fukui, Y, Ueyama, Y, Tamaoki, N., Kawamoto, T., Taniguchi, S., and
Shibuya. M. Amplification of the structurally and functionally altered epidermal
growth factor receptor gene (c-erbB) in human brain tumors. Mol. Cell. Biol., 8:
1816-1820, 1988.
Wong. A. J.. Ruppert, J. M.. Bigner. S. H., Grzeschik, C. H.. Humphrey, P. A., Bigner.
D. D.. and Vogelstein. B. Structural alterations of the epidermal growth factor receptor
gene in human gliomas. Proc. Nati. Acad. Sci. USA, 89: 2965-2969, 1992.
Sugawa. N.. Ekstrand. A. J., James, C. D., and Collins, V. P. Identical splicing of
aberrant epidermal growth factor receptor transcripts from amplified rearranged genes
in human glioblastomas. Proc. Nati. Acad. Sci. USA. 87: 8602-8606, 1990.
Siegfried, J. M.. Ellison. D. J.. Resau, J. H.. Miura. I., and Testa, J. R. Correlation of
modal chromosome number of cultured non-small cell lung carcinomas with DNA
index of solid tumor tissue. Cancer Res.. 51: 3267-3273, 1991.
Yunis. J. J. New chromosome techniques in the study of human neoplasia. Human
Pathol., 12: 540-549, 1981.
F. Mudili.ni (ed.I. ISCN (1991): Guidelines for Cancer Cytogenetics, Supplement to
An International System for Human Cytogenetic Nomenclature. Basel: S. Krager,
1991.
Soboi, R. E., Astarita. R. W., Hofeditz, C., Masui, H., Fairshter, R., Royston, I., and
Mendelsohn, J. Epidermal growth factor receptor expression in human lung carcino
mas defined by a monoclonal antibody. J. Nati. Cancer Inst., 79: 403^407, 1987.
Testa, J. R.. and Siegfried, J. M. Chromosome abnormalities in non-small cell lung
cancer. Cancer Res. (Suppl.) 52: 2702s-2706s. 1992.
Spurr, N. K.. Solomon. E., Janssen. M.. Sheer. D.. Goodfellow, P. N., Bodmer, W. F.,
and Vennstrom. B. Chromosome localization of the human homologues to the oncogenes erbA and B. EMBO J., 3: 159-163, 1984.
3220
Downloaded from cancerres.aacrjournals.org on August 20, 2015. © 1993 American Association for Cancer
Research.
Expression of Mutated Epidermal Growth Factor Receptor by
Non-Small Cell Lung Carcinomas
Irma E. Garcia de Palazzo, Gregory P. Adams, Padma Sundareshan, et al.
Cancer Res 1993;53:3217-3220.
Updated version
E-mail alerts
Reprints and
Subscriptions
Permissions
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/53/14/3217
Sign up to receive free email-alerts related to this article or journal.
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Department at pubs@aacr.org.
To request permission to re-use all or part of this article, contact the AACR Publications
Department at permissions@aacr.org.
Downloaded from cancerres.aacrjournals.org on August 20, 2015. © 1993 American Association for Cancer
Research.